EUVIMEDEUVIMED entdecken
Crossref

Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity

Yee Man AuYeung iD, Zheng Zeng, Luyao Coco Zhou, Jiani Zhan, Zhe Wang, JiaXin Guo, Renhao Li, Yangfan Wu, Choa Mun, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura und 1 weitere

Small · 2026-02 · 22 (7)

DOI: 10.1002/smll.202505791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 15.12.2025. Verfasst von Yee Man AuYeung und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, 000, Hong…. Hauptthemen laut MEDLINE: Dendritic Cells, Bacteriophage M13, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Filamentous M13 phages are promising self‐adjuvanting nanoparticles for cancer immunotherapy, but their efficacy remains limited by antigen versatility and immune targeting. Here, SCP is developed as an M13 phage‐based vector that conjugates antigens via a SpyCatcher‐SpyTag interface and presents dendritic cell (DC)‐targeting peptides to enhance antigen uptake. SCP activates DCs in vitro, upregulating co‐stimulatory markers and inflammatory gene signatures, which subsequently enhances T cell cytotoxicity. In vivo, SCP can be administered subcutaneously as a vaccine adjuvant or intratumourally as a therapy in multiple murine tumour models. SCP induces robust local inflammation, immunogenic cell death, and in situ tumour antigen release, driving tumour‐specific cytotoxic T cell responses without requiring predefined neoantigens. Beyond promoting immune infiltration, SCP also reduces neovascularization, downregulates immune checkpoints, and elicits durable systemic immunity to prevent recurrence. Overall, SCP offers a scalable, cost‐effective platform for enhancing tumour immunogenicity, bypassing the need for predefined neoantigen selection and exogenous vaccine production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsBacteriophage M13NeoplasmsAnimalsMiceMice, Inbred C57BLImmunotherapyHumansNanoparticlesCancer Vaccines

Stichwörter der Autor:innen

biomedical engineeringcancer immunotherapynanotechnologyphage displaysynthetic biology

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • School of Biomedical Sciences and School of Biomedical Engineering, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, 000, Hong Kong SAR.
  • Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, 000, Hong Kong.
  • Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518000, China.
  • Department of Pathology, Nippon Veterinary and Life Science University, Tokyo, 180-8602, Japan.
  • Department of Pathology, Graduate School of Medicine, Fujita Health University, Toyoake, 470-1192, Japan.
  • Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8654, Japan.

ORCID-Profile: Yee Man AuYeung, Jian-Dong Huang

Zitieren

APA

AuYeung, Y. M., Zeng, Z., Zhou, L. C., Zhan, J., Wang, Z., Guo, J., Li, R., Wu, Y., Mun, C., Yamamoto, M., Tsukamoto, T., Nomura, S., & Huang, J. D. (2026). Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity. Small, 22(7). https://doi.org/10.1002/smll.202505791

Vancouver

AuYeung YM, Zeng Z, Zhou LC, Zhan J, Wang Z, Guo J, et al. Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity. Small. 2026;22(7). doi:10.1002/smll.202505791

BibTeX
@article{AuYeung2026,
  author = {AuYeung, Yee Man and Zeng, Zheng and Zhou, Luyao Coco and Zhan, Jiani and Wang, Zhe and Guo, JiaXin and Li, Renhao and Wu, Yangfan and Mun, Choa and Yamamoto, Masami and Tsukamoto, Tetsuya and Nomura, Sachiyo and Huang, Jian-Dong},
  title = {Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {7},
  doi = {10.1002/smll.202505791}
}
Kostenlos starten →